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Abstract 
Background: The pursuit for clarity in diagnostic and treatment pathways for the complex, chronic condition of 
myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) continues. This systematic review raises a novel 
question to explore possible overlapping aetiology in two distinct conditions. Similar neurocognitive symptoms and 
evidence of d-lactate producing bacteria in ME/CFS raise questions about shared mechanisms with the acute condi-
tion of d-lactic acidosis (d-la).
Methods: d-la case reports published between 1965 and March 2016 were reviewed for episodes describing both 
neurological symptoms and high d-lactate levels. Fifty-nine d-la episodes were included in the qualitative synthesis 
comparing d-la symptoms with ME/CFS diagnostic criteria. A narrative review of d-la mechanisms and relevance for 
ME/CFS was provided.
Results: The majority of neurological disturbances reported in d-la episodes overlapped with ME/CFS symptoms. 
Of these, the most frequently reported d-la symptoms were motor disturbances that appear more prominent during 
severe presentations of ME/CFS. Both patient groups shared a history of gastrointestinal abnormalities and evidence 
of bacterial dysbiosis, although only preliminary evidence supported the role of lactate-producing bacteria in ME/CFS.
Limitations: Interpretation of results are constrained by both the breadth of symptoms included in ME/CFS diagnos-
tic criteria and the conservative methodology used for d-la symptom classification. Several pathophysiological mecha-
nisms in ME/CFS were not examined.
Conclusions: Shared symptomatology and underlying microbiota–gut–brain interactions raise the possibility of 
a continuum of acute (d-la) versus chronic (ME/CFS) presentations related to d-lactate absorption. Measurement of 
d-lactate in ME/CFS is needed to effectively evaluate whether subclinical d-lactate levels affect neurological symptoms 
in this clinical population.
Keywords: Acidosis, lactic, Dysbiosis, Fatigue syndrome, chronic, Encephalomyelitis, myalgic, Microbiota-gut–brain, 
Neurological symptoms
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Background
Myalgic encephalomyelitis/chronic fatigue syndrome 
(ME/CFS) is a complex condition with evidence of 
multi-systemic dysfunction. The primary symptom of 
post-exertional fatigue is accompanied by heterogeneous 
neurological, immune, cardiovascular, respiratory and/or 
gastrointestinal manifestations [1]. Research efforts con-
tinue to search for biomarkers to aid etiological under-
standings and treatment options for this debilitating 
condition. It has been proposed that some neurological 
symptoms may be related to an imbalance of commensal 
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gut bacteria (i.e., gut dysbiosis [2]). Within ME/CFS, evi-
dence of gut dysbiosis [3, 4] and associations between 
microbial genus and symptom expression [5] raise ques-
tions about whether gut dysbiosis plays a causative or 
mechanistic role in onset, maintenance and/or sympto-
matic variability. The mechanisms are not clear because 
microbe–gut–brain interactions can occur through sev-
eral pathways (i.e., central, autonomic, and enteric nerv-
ous systems; neuroendocrine and neuroimmune; enteric 
microbiota) [6–8]. Investigations of other conditions 
with similar presentations may aid the current etiologi-
cal understanding of ME/CFS. d-Lactic acidosis (d-la) is 
an acute condition that shares some similar features with 
ME/CFS and provides a clear example of the microbe–
gut–brain interaction.
d-la is a type of metabolic acidosis with the primary 
presentation of encephalopathy (i.e., impaired mental 
state including confusion, loss of memory or cognitive 
capacity) [9]. d-la has also been referred to as “d-lactate 
neuropathy” or “d-lactate encephalomyelitis” in humans 
and “floppy kid syndrome”, or “drunken lamb syndrome” 
in animals. Originally described in ruminants [10], the 
condition has now been observed in multiple human case 
reports since 1979 [11].
The neurological symptoms and associated biochemi-
cal imbalances of d-la appear to result from gastrointes-
tinal dysfunction. d-la is most commonly observed in 
patients with short bowel syndrome (SBS), often after 
surgery or removal of a section of the small bowel [12]. 
This reduced length diminishes the small bowel’s func-
tional capacity to effectively metabolise carbohydrates 
leading to excessive bacterial fermentation in the colon 
[13]. Small intestinal carbohydrate malabsorption precip-
itates an increase in colonic acidity and the consequential 
overgrowth of certain species of colonic microbiota that 
produce an abundance of d-lactate. Healthy humans have 
the capacity to effectively metabolise d-lactate [14, 15]. 
However, the combination of high levels and insufficient 
d-lactate metabolic capacity can result in excess accumu-
lation of d-lactate in the blood and absorption within the 
brain, resulting in the neurological symptoms character-
istic of d-la [13].
Higher levels of d-lactate producing bacteria (such 
as Streptococcus and Enterococcus) have been identi-
fied in stool samples from patients with ME/CFS [4]. 
This evidence, combined with some similar neurologi-
cal symptoms in both conditions, has led to compari-
son with d-la and proposal of the d-lactate hypothesis 
for ME/CFS. Accordingly, this hypothesis suggests that 
an increased abundance of d-lactate producing bacteria 
and suspected higher circulating levels of d-lactate may 
contribute to the neurological manifestations of ME/CFS. 
However, this hypothesis has not been systematically 
evaluated. Neither plasma nor urine d-lactate levels have 
been documented in ME/CFS to date. This lack of clini-
cal d-lactate data coupled with confusion surrounding 
the degree of symptom overlap between d-la and ME/
CFS provide the rationale for this qualitative review. To 
help ascertain the relevance of the d-lactate hypothesis 
for ME/CFS, Part A of this review aims to (a) systemati-
cally summarise published d-la episodes that report neu-
rological symptoms and d-lactate levels; and (b) examine 
the overlap between d-la and ME/CFS symptom. Part 
B provides a narrative review of proposed neurological 
mechanisms in d-la to examine its relevance for ME/CFS 
aetiology.
Main text
Part A. Systematic qualitative review
Method
MEDLINE (via Ebscohost) and PubMed databases were 
searched for publications from 1965 to April 1 2016. 
To obtain papers referring to d-la, the following search 
terms were used: d-lact* AND (acidosis OR encephalopa-
thy OR neuropathy). These databases were also searched 
for ME/CFS articles referring to acidosis (search terms: 
acidosis AND (“chronic fatigue syndrome” OR “myal-
gic encephalomyelitis”). Reference lists from articles 
obtained were manually screened to find other relevant 
references. Figure  1 shows the PRISMA flowchart for 
identification, screening and article exclusion.
Qualitative synthesis
Sixty-eight case reports were screened for inclusion in 
the qualitative synthesis (see Table 1). Case reports were 
screened in a two-step process. The first stage of this pro-
cess involved identifying case reports that reported both 
d-lactate levels and neurological symptoms during an 
episode of d-la. Fifteen case reports were excluded at this 
stage due to an inability to obtain full-text or inadequate 
reporting of neurological symptoms and/or d-lactate lev-
els. A serum d-lactate level of greater than 3.0  mmol/L 
has been proposed as a marker for d-la diagnosis [16]. 
However, using this criterion for exclusion was consid-
ered to be inappropriate when there were varying meas-
urement methods used throughout the case reports. To 
reduce bias in case report selection, all cases that meas-
ured d-lactate and indicated that the patient’s d-lactate 
level was ‘high’ or above the ‘normal’ range, as stipulated 
by the authors and relevant measurement method, were 
included. Only one episode was excluded [17] when 
plasma d-lactate fell within the normal range according 
to the chosen method of measuring d-lactate defined 
within this case report. Across the episodes reviewed, 
there were considerable discrepancies between sam-
pling and measurement methods (see Additional file  1: 
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Fig. 1 PRISMA flowchart of systematic search and article selection. Asterisk eligibility criteria included episodes of d-lactic acidosis where both 
neurological symptoms and d-lactate levels were reported
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Table S1). A discussion paper on measurement issues and 
analyses is being compiled by our team and beyond the 
scope of the current review.
During the second stage of screening, the remaining 
53 case reports were independently assessed for quality 
by a team of three critical appraisers. Each article was 
assessed by two appraisers using the checklist developed 
by The Joanna Briggs Institute [18] based on the CARE 
Guidelines [19] established to improve the quality of 
reporting clinical cases. Appraisers rated (Yes, Unclear, 
No or N/A) on the eight items pertaining to (1) Demo-
graphic characteristics; (2) Patient history; (3) Current 
clinical condition; (4) Diagnostic tests; (5) Treatment/
intervention; (6) Post-intervention clinical condition; (7) 
Table 1 d-Lactic acidosis case reports screened for qualita-
tive synthesis
Episode 
code #
References Included Reasons for exclusion
1 [20] N d-Lactate measurement not 
specified
2 [17] N Plasma d-lactate within nor-
mal range
3 [21] N d-Lactate measurement not 
specified
4 [22] Y
5 [23] N d-Lactate measurement not 
specified
6 [24] Y
7 [25] N d-Lactate not d-la; No com-
parison between d-lactate 
and neurological symptoms
8 [26] Y
9 [27] Y
10 [28] Y
11 [29] Y
12a and 12b [30] Y
13 [31] Y
14 [32] Y
15 [33] Y
161 and  162 [34] Y
17 [35] Y
18 [36] Y
19 [37] Y
20 [38] Y
21 [39] Y
22 [15] N d-Lactate levels not presented 
in relation to neurological 
symptoms
23 [40] Y
24 [41] Y
25 [42] Y
26* [43] Y
27 [44] Y
28 [45] Y
29 [46] Y
30 [47] Y
31 [48] Y
32 [49] N Unable to obtain full-text
33 [50] Y
341 and  342 [51] Y
35 [52] Y
36* [53] Y
37 [54] Y
38 [55] N Neurological symptoms not 
specified
39* [56] Y
40 [57] Y
41 [58] Y
Table 1 continued
Episode 
code #
References Included Reasons for exclusion
42* [59] Y
43 [60] Y
44 [11] Y
45 [61, 62] N Same case for both references; 
d-lactate levels not specified
46 [63] N d-Lactate not measured
47a and 47b [64] Y
48 [65] Y
49 [66] Y
50 [67] Y
51a and 51b [68] Y
52 [69] Y
53 [70] Y
54 [71] N Unable to obtain English 
full-text
55 [72] Y
56 [73] Y
57 [74] Y
58a and 58b [75] Y
59 [76] Y
60 [77] Y
61 [78] N d-Lactate measurement not 
specified
62 [79] Y
63 [80] N Neurological symptoms not 
specified
64 [16] Y
65 [81] Y
66 [82] Y
67 [83] N d-Lactate only measured dur-
ing intervention
Subscript numbers (1 and 2) indicate separate episodes for the same patient. The 
letters a and b identify different patient cases reported in the same reference. 
Episodes from non-SBS patients are marked with an asterisk. Episodes included 
in qualitative synthesis simultaneously reported at least one high D-lactate level 
(from blood or urine analysis) and documented neurological symptoms
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Adverse events; and (8) Take away lessons. Items 1–4 
were prioritised as they were most relevant for the focus 
of this review. When comparing ratings across these four 
items, most articles (47/53, 90.1%) were rated as ‘Yes’ by 
both critical appraisers. For the remaining 6 articles, at 
least one reviewer provided a rating of ‘Unclear’ on an 
item. Discrepancies in ratings were discussed and the 
appraisers agreed that all articles adequately covered 
these priority domains and were deemed appropriate for 
inclusion in the qualitative synthesis.
Case reports that described multiple episodes (either 
for the same patient or different patients) were included 
as separate episodes if they met the eligibility criteria. 
From the 53 case reports, a total of 59 episodes were 
identified and included for qualitative synthesis. Each 
episode was reviewed with information about patient 
demographics, medical history, comorbid conditions, 
proposed triggers, neurological symptoms, non-neuro-
logical symptoms, d-lactate levels, l-lactate levels, anion 
gap, pH levels, microbial composition and treatment tab-
ulated (Additional file 1: Table S1).
Determining ME/CFS and d‑la symptom overlap
Reported d-la symptoms (neurological and non-neu-
rological) were compared with ME/CFS International 
Consensus Criteria (ICC; [1]. Comorbid mood symp-
toms (including anxiety and depression) not required 
for ME/CFS diagnosis but frequently experienced by 
patients were also included for comparison with d-la 
presentations. d-la symptoms were classified as ‘match‑
ing’ ME/CFS symptoms or ‘ambiguous/other’. d-la symp-
toms were only classified as matching if terminology was 
directly comparable to the symptoms described in the 
ICC (see Table 2). All other symptoms were categorised 
as ambiguous/other. 
Neurological symptoms
As neurological symptoms were the primary focus of this 
review, further categorisation was used to obtain more 
information about the types of neurological symptoms 
that accompany a d-la presentation. The ambiguous/
other neurological symptoms were delineated into ME/
CFS categories B1–B4, speech and consciousness sub-
groups (see Table  2). Reports of altered consciousness 
formed a distinct subcategory (consciousness) to identify 
the proportion of patients that presented with this more 
severe neurological symptom.
Speech and language impairment may have shared 
pathophysiology with other motor or neurocognitive 
disturbances. The ME/CFS ICC describes ‘slow speech’ 
without mentioning any other specific speech or lan-
guage impairments [1]. Impaired information process-
ing and word retrieval have been described as cognitive 
manifestations of ME/CFS, with speech therapy being a 
suggested treatment option [84]. The transient speech 
and language symptoms (e.g. dysarthria and/or slurred 
and incoherent speech) in d-la are likely to be overt 
behavioural manifestations of underlying muscle weak-
ness and/or neurocognitive disturbances. However, 
without further information from each report, speech 
symptoms (excluding ‘slow speech’) were grouped as a 
subcategory for further investigation.
Conservative methodology
As highlighted by the aforementioned distinct classifi-
cation of speech and language symptoms, we chose to 
pursue a conservative method of symptom categorisa-
tion. Several other ambiguous d-la symptoms were highly 
suggestive of ME/CFS and more likely to reflect discrep-
ancies in terminology rather than different symptoma-
tology per se. Inconsistent assessment and reporting of 
symptoms can reflect differences between patient demo-
graphics (i.e., age or sex), disciplines, and professional 
settings. This is particularly pertinent when consider-
ing comparisons between terminology used to describe 
chronic (i.e., ME/CFS) versus acute (i.e., d-la) presenta-
tions. For example, a patient presenting with ‘fluctuat-
ing consciousness’ or ‘comatose’ may preclude further 
neurological assessment and thus limit reporting of other 
covert symptoms. Similarly, the observable nature of 
motor and speech/language symptoms may be more fre-
quently reported during an acute hospital presentation 
unlike some neurocognitive symptoms that require more 
specific testing and comparative measures to notice, for 
example a deterioration in memory, attention and clar-
ity of thought. In another example, ‘slowed cerebellar 
function’ was used to describe d-la symptoms. This term 
is likely to reflect similar ME/CFS motor disturbances. 
However, the ICC does not specifically refer to ‘slowed’ 
movement, hence this symptom was classified as ambig‑
uous/other. Consequently, our method of clinically com-
paring ME/CFS and d-la symptoms was conservative and 
chosen to ensure that symptom overlap was not inflated.
The presence of each reported d-la symptom was iden-
tified by episode number (see Table 1). This enabled fre-
quencies and percentages to be calculated for both broad 
(A–D) and specific (B1–B4, C1–5, D1–4) ME/CFS ICC 
categories. Many episodes reported multiple neurologi-
cal symptoms both within and between different subcat-
egories i.e. neurocognitive impairments (B1) and motor 
disturbances (B4b). In these circumstances, each episode 
was only counted once for each specific subcategory. 
Likewise, an episode was only included once when calcu-
lating the presence of symptoms in each broad category, 
i.e. neurological impairments (B). Frequencies and per-
centages were calculated for each symptom category and 
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Table 2 Mapping overlap between  myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and d-lactic acidosis 
(d-la) symptoms
ME/CFS International Consensus Criteria [1] d-la symptoms mapped to ME/CFS criteria
Matching Ambiguous/other
A. Postexertional neuroimmune exhaustion 
(compulsory)
A. Lethargy/fatigue
B. Neurological impairments (at least one symp-
tom from 3 of the 4 categories)
 B1. Neurocognitive impairments
 B2. Pain
 B3. Sleep disturbances
 B4a. Neurosensory and perceptual and
 B4b. Motor disturbances
B1. Encephalopathy/Mental confusion/disorien-
tation/dazed/Concentration difficulties/Slow 
processing and responding to questions/
slow speech
B2. Headaches/Muscle pain
B3. Drowsiness/sleepiness/somnolence
B4a. Blurred vision
B4b. Weakness/hypotonic (lowered muscle 
tone)/flaccidity/impaired gait (staggering/
wide/ataxic/unsteady/instability)/ataxia 
(movement and co-ordination difficulties)/
impaired balance
B1. Altered mental state/cortical dysfunction (e.g., disori-
ented to date, time, place and space)/delirium/blunted 
judgment/abnormal EEG
B4a. Hallucinations (visual and auditory)/delusions/para-
noid ideation
B4b. Slowed cerebellar function/movement/dysiadochoki-
nesia (difficulty performing rapid movement)/impaired 
reflexes/Neuropathy (fine motor coordination difficul-
ties)/unable to grasp objects/Ptosis (eye drooping)/
Asterixis (hand ‘flapping’/tremor)/Spasms: nystagmus 
(eye spasms)/opisthotonos (muscle spasms leading to 
hyperextended posture)/Bruxism
Speech symptoms: Slurred and incoherent speech/dysarthria 
(speech pronunciation difficulties, weak muscles effecting 
speech)/thickened speech/ataxic speech (explosive—
pauses between syllables)
Consciousness: Altered/fluctuating/comatose/intermit-
tent coma/stupor/induced sleep/depressed level of 
consciousness/obtunded/fluctuating from unrousable 
to alert
C. Immune, gastro-intestinal and genitourinary 
impairments (at least one symptom from 3 of 
the 5 categories)
 C1. Flu-like symptoms
 C2. Prone to viral infections
 C3. Gastro-intestinal abnormalities: nausea, 
abdominal pain, irritable bowel syndrome, 
bloating
 C4. Genitourinary symptoms
 C5. Sensitivities to food, medication, odours or 
chemicals
C3. Gastrointestinal symptoms*:
Increased diarrhea/bowel movements
Nausea/vomiting
Diffuse abdominal pain
D. Energy production/transportation impairments 
(at least 1 symptom)
 D1. Cardiovascular: orthostatic intolerance (ina-
bility to tolerate an upright position), postural 
orthostatic tachycardia syndrome, palpitations, 
arrhythmias, hypotension, dizziness, pallor
 D2. Respiratory: labored breathing, air hunger, 
fatigue of chest wall muscles
 D3. Thermostatic instability: lowered body 
temperature, cold extremities, marked diurnal 
fluctuations, sweating, episodic feverishness
 D4. Intolerance to temperature extremes
D1. Inability to stand/sit upright/Tachycardia 
(rapid heart rate)/Respiratory arrhythmia/
Hypotension/low blood pressure/Dizziness/
Pallor
D2. Breathing difficulties: hyperpnoea (deep 
breathing)/dyspnoea (shortness of breath)/
tachypnea (rapid breathing)/Kussmaul (deep 
and laboured)/breathlessness/hyperventila-
tion
D3. Body temperature changes (high or low)
D1. Bradycardia (slowed heart rate)
D2. Respiratory acidosis and hypercarbic respiratory failure
Comorbid Mood and Behavioural Disturbances
1. Depressive symptoms
2. Anxiety symptoms
1. Unhappy/agitation/irritability
2. Anxiety
Irrational/unusual/disturbed behavior/aggressive/hostile/
abusive/combative/uncooperative behavior/euphoria/
aloofness
Uncategorized d-la symptoms
Metabolic acidosis
Other abnormalities:
dehydration/cravings (water, cigarettes)/excessive thirst
Acute renal failure/hyperchloremic acidosis/liver dysfunction
ME/CFS broad category B. Neurological impairments are highlighted as the primary focus of this review and to show three subcategories of delineation under 
ambiguous/other symptoms (i.e., in accordance with specific ICC criteria (B1 – B4), speech/language symptoms, and level of consciousness)
* Gastro-intestinal symptoms associated with short bowel syndrome or the patient’s medical history were not included as symptoms of d-la. Only reports of a change 
in gastrointestinal symptoms were included
ambiguous/other: symptoms that were not clearly identified as consistent with ME/CFS presentation (see Table 2 for detailed symptom delineation), d-la d-lactic 
acidosis, matching: mapped overlap between ME/CFS and d-la symptoms, ME/CFS myalgic encephalomyelitis/chronic fatigue syndrome
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delineated by available demographic details (age and sex). 
Episodes were classified as paediatric (≤17 years) or adult 
(≥18 years).
Results
Systematic summary of d-la episodes
A total of 59 episodes of d-la reported both neurologi-
cal symptoms and d-lactate levels. The average patient 
age during d-la presentation was 29.9 years (SD = 21.0). 
Twenty-two paediatric (age range 10 months to 16 years, 
M = 7.1 years, SD = 4.5 years) and 37 adult (age range 
18–60 years, M = 43.4 years, SD = 13.9 years) episodes 
were examined. There were 35 male and 23 female epi-
sodes with similar sex ratios documented for adult 
males (n  =  20) and females (n  =  17). Patient sex was 
not identified in one paediatric case. A predominance 
of male paediatric episodes (n =  15) were found com-
pared with female paediatric episodes (n = 6). d-la epi-
sodes were primarily from patients with a history of 
SBS (55/59, 93.2%). The four patient episodes without 
SBS presented with propylene glycol intoxication [43], 
chronic pancreatitis [53], acute lymphoblastic leukae-
mia [56], and surgery error [59]. Table 3 summarises the 
frequency and percentage of reported d-la symptoms 
by age (paediatric and adult), sex (male and female) and 
total episodes.
Table 3 shows some evidence of shared symptomatol-
ogy across each broad ME/CFS ICC category. The high-
est percentage of overlap was found for neurological 
symptoms. Other symptoms specific to d-la were also 
frequently reported (e.g., metabolic acidosis). ME/CFS 
symptom categories are discussed sequentially to exam-
ine similarities with d-la symptoms.
Overlap between d-la and ME/CFS symptoms
Post‑exertional neuroimmune exhaustion
This ME/CFS symptom describes a chronic pattern 
of excessive and disproportionate fatigue upon exer-
tion. This is the core compulsory symptom of ME/CFS 
[1]. In the context of the chronicity of ME/CFS symp-
toms, it is difficult to directly compare this pattern of 
post-exertional exhaustion with an acute presentation 
of d-la. Nevertheless, one quarter of patients reported 
symptoms of lethargy and fatigue during a d-la episode 
(15/59, 25.4%). In contrast, all ME/CFS patients experi-
ence fatigue and lethargy as it is a required diagnostic 
criterion. The lower frequency of fatigue reported in 
d-la, may accurately reflect characteristic distinctions 
between the two conditions. Alternatively, an acute pres-
entation of d-la can include fluctuating levels of con-
sciousness and hence symptoms of fatigue may be less 
relevant and/or underreported within this emergency 
hospital setting.
Neurological impairments
Episodes reviewed in this qualitative synthesis required 
neurological symptoms to be reported (as an inclusion 
criterion), accordingly, all episodes of d-la reported at 
least one neurological impairment. The majority of neu-
rological symptoms that were reported overlapped with 
ME/CFS symptomatology (52/59, 88.1%). The frequen-
cies of matching ME/CFS neurological symptoms were 
similar when comparing paediatric (19/22, 86.4%) and 
adult (33/37, 89.2%) episodes as well as male (30/35, 
85.7%) and female (21/23, 91.3%) episodes. Ambiguous/
other neurological impairments (e.g., altered mental state 
or cortical dysfunction) were also frequently reported 
(45/59, 76.3%). The more severe neurological symptom of 
an altered level of consciousness was reported in 13 epi-
sodes (22.0%). Five case reports documented the patient’s 
altered consciousness as the only neurological symptom 
during the d-la episode. The remaining reports described 
additional neurological symptoms and a deterioration in 
symptoms affecting consciousness.
When considering more specific types of neurologi-
cal impairments, motor disturbance (B4b) was the most 
frequently reported matching ME/CFS neurological 
symptom (42/59, 71.2%, see Fig.  2). This was notably 
higher than the other neurological symptoms (B1. Neu-
rocognitive  =  25/59, 42.4%, B2. Pain  =  3/59, 5.1%, B3. 
Sleep  =  10/59, 16.9%, B4a. Neurosensory and Percep-
tual = 2/59, 3.4%). Common motor disturbances in ME/
CFS include muscle weakness, clumsiness, balance and 
coordination difficulties [84]. The ICC noted that the 
presence of balance and gait instabilities are more fre-
quently observed in severe cases [1]. Ambiguous/other 
neurocognitive, neurosensory, perceptual and motor dis-
turbances were reported in 37.3% of total d-la episodes 
(22/59). Within these 22 episodes, 90.9% (20/22) of epi-
sodes simultaneously reported at least one matching 
neurological symptom akin with ME/CFS diagnostic cri-
teria. Therefore, there was considerable overlap between 
matching symptoms and ambiguous/other neurological 
symptoms.
Approximately half of d-la episodes reported impair-
ments in speech (30/59, 50.9%). Notably, all episodes that 
reported speech and language impairments also reported 
at least one other ME/CFS-matching neurological 
impairment, which may reflect the shared pathophysiol-
ogy that underlies the behavioural manifestation of overt 
speech symptoms.
Immune, gastrointestinal and genitourinary impairments
The majority of d-la episodes were from patients with 
SBS (55/59, 93.9%). As such, these patients had a his-
tory of extensive gastrointestinal abnormalities. The case 
report of the patient with leukaemia [56] was the only 
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episode of d-la that did not report any gastrointestinal 
symptoms during the acute stage or prior history. This 
episode was also an exception as it was the only episode 
of d-la without metabolic acidosis (discussed below). A 
change in ME/CFS-matching gastrointestinal symptoms 
associated with the d-la presentation was only reported 
in 22.0% of the total episodes (13/59). These changes 
included an increase in diarrhoea, nausea, vomiting and/
or abdominal pain/distension.
Immune or genitourinary impairments (matching or 
ambiguous/other) were not specifically reported during 
d-la episodes. Conversely, immune symptoms are a pri-
mary component of ME/CFS as a neuro-immune con-
dition with evidence of immune abnormalities [85] and 
autoimmune mechanisms [86].
Energy production and transportation impairments
ME/CFS-matching energy production and transportation 
impairments were reported in 33.9% (20/59) of total d-la 
episodes. These symptoms were more frequently reported 
in male (15/35, 42.9%) compared with female episodes 
(5/23, 21.7%; see Table 3). Ambiguous/other cardiovascu-
lar (bradycardia) and respiratory symptoms (respiratory 
acidosis and hypercarbic respiratory failure) were docu-
mented during two adult male episodes (2/59, 3.4%).
Comorbid mood and behavioural disturbances
Mood disturbances are not included in ME/CFS diagnos-
tic criteria. However, patients with ME/CFS frequently 
experience comorbid anxiety and depressive symptoms 
[1, 87]. Matching mood (depressive and anxiety) symp-
toms were reported in 13.6% of d-la episodes (8/59). 
Ambiguous/other ME/CFS mood and behavioural distur-
bances were described in 22.0% of d-la episodes (13/59). 
The higher frequency of ambiguous/other mood and 
behavioural disturbances seen in paediatric male (6/15, 
40.0%) compared to paediatric female episodes (0/6) may 
reflect the tendency for boys to externalise behaviours 
more than girls [88].
Other symptoms (non‑ME/CFS)
Metabolic acidosis as defined by blood pH values below 
7.35 [89] and/or as stipulated in each case report based 
on patients’ anion gap, was confirmed in all except one 
episode of d-la (58/59, 98.3%). Metabolic acidosis occurs 
when there is a decrease in serum bicarbonate, excess 
hydrogen ions and, commonly, a lower pH value sug-
gestive of acidosis [90]. However, in some situations an 
underlying metabolic acidosis can be reflected in higher 
pH values that are indicative of alkalosis but are second-
ary to a metabolic acidosis, sometimes referred to as 
Fig. 2 Percentages of d-lactic acidosis (d-la) episodes that reported ME/CFS matching and ambiguous/other neurological impairments. Total per-
centages are reported for neurocognitive symptoms (B1), pain (B2), sleep disturbance (B3), neurosensory and perceptual disturbances (B4a), motor 
disturbances (B4b), speech symptoms, and altered consciousness. N.B. The same episode may be represented multiple times for both matching and 
ambiguous/other symptom groups across all neurological impairment subcategories
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a compensatory process [90]. In Mendu et  al. [56] the 
authors described the normal serum pH values (7.35–
7.45) as a “compensated metabolic acidosis” due to simul-
taneous higher l-lactate levels observed in this patient (p. 
90). Metabolic acidosis is a primary marker of d-la but is 
not described in ME/CFS diagnostic criteria. Blood pH 
values are not routinely measured in ME/CFS, therefore, 
the symptomatic overlap cannot be determined.
Other abnormalities such as dehydration, cravings and 
excessive thirst were infrequently reported in the d-la 
episodes (9/59, 15.3%). Acute renal failure, hyperchlo-
remic acidosis and liver dysfunction were reported in 
three separate episodes (3/59, 5.1%).
Discussion
Examples of matching ME/CFS and d-la symptoms were 
found throughout the d-la case reports. More than 96.6 
per cent (57/59) of d-la episodes reported at least one 
matching ME/CFS symptom. Whilst there was consider-
able overlap, some symptoms of both ME/CFS and d-la 
were distinct. Figure  3 provides an overview of shared 
and distinct symptoms in these acute and chronic clinical 
conditions.
This qualitative synthesis has confirmed that the type 
of neurological impairments reported during d-la epi-
sodes are similar to those experienced by ME/CFS 
patients. However, the most commonly reported motor 
disturbances in d-la are considered a more severe pres-
entation within ME/CFS [1]. This may reflect differing 
pathophysiology or alternatively may support a proposal 
for both conditions to lie on a continuum. ME/CFS may 
fall at one end as a chronic condition with fluctuating 
severity and d-la at the other extreme as an exacerba-
tion of an acute presentation (see Fig.  3). The fluctuat-
ing neurological symptoms that present in both d-la and 
ME/CFS may vary in severity and the corresponding 
treatment response [66]. Htyte et al. [40] described these 
transient symptoms as “usually mild and self-limiting in 
patients with normal renal function” (p. 1435), highlight-
ing the individual variation in presentation and report-
ing of symptoms with less severe symptoms unlikely to 
prompt acute emergency care.
Some key areas of disparity between d-la and ME/CFS 
symptoms related to immune impairments and meta-
bolic acidosis. These results may accurately reflect patho-
physiological differences between the two conditions. 
Alternatively, some other plausible explanations warrant 
consideration. The lack of reports relating to specific 
immune symptoms in d-la may be related to symptom 
prioritisation during an acute presentation. Reports of 
bacterial infection preceding d-la onset, bacterial over-
growth during the d-la episode and response to antibi-
otic treatment (see Additional file  1: Table  S1), suggest 
that immune dysfunction may still be relevant for d-la 
patients.
Without measurement of blood pH levels the preva-
lence of metabolic acidosis in ME/CFS is unknown. Other 
research raises questions about the possibility of similar 
mechanisms of metabolic acidosis (or the compensatory 
acidosis described above) in ME/CFS. Alkalosis in skel-
etal muscles may result in a compensated acidosis in the 
blood, precipitating hyperventilation [91]. This theory 
Fig. 3 Proposed continuum of d-lactic acidosis and ME/CFS symptoms. A continuum showing, from left to right; distinct myalgic encephalomyelitis/
chronic fatigue syndrome (ME/CFS) symptoms, shared and distinct d-lactic acidosis (d-la) symptoms. Continuum also shows chronic compared to 
acute presentations
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has been proposed from evidence of hyperventilation in 
patients with ME/CFS [92] and an inverse association 
between skeletal muscle pH and cerebral blood flow [91]. 
Compared to sedentary controls, ME/CFS patients have 
higher skeletal muscle pH at rest [93] and at recovery 
after exercise [93]. Alkalosis in skeletal muscle has been 
proposed as a mechanism effecting orthostatic and neu-
rocognitive ME/CFS symptoms [91]. Blood acidosis can 
also directly alter the function of cellular membranes [91], 
therefore, our current understanding of the mechanisms 
involved remain rudimentary. Routine assessment of 
blood pH levels in ME/CFS will ascertain the prevalence 
of metabolic acidosis/alkalosis for this clinical population.
Limitations
These results need to be considered with an aware-
ness of potential methodological limitations. Firstly, the 
inclusion criteria for selected case reports in this review 
may have been problematic. Although unavoidable, the 
requirement of neurological symptoms during d-la epi-
sodes may have increased reporting bias during this 
review process leading to an exaggerated focus on neu-
rological symptoms. However, the effect of this limitation 
may be moderated when considering the high percent-
age of case reports meeting both the eligibility criteria of 
describing neurological symptoms and d-lactate meas-
urement during the episode (80.0%).
Findings from this qualitative review are also limited by 
the lack of standardised procedures used when report-
ing symptoms in case reports. Differences in assessment 
procedures and terminology used for reporting neuro-
logical symptoms may impede accurate interpretation. 
Some ambiguous/other symptoms described as distinct 
may share similar pathophysiology. This may be particu-
larly pertinent for speech symptoms. On the one hand, 
the results may underestimate the level of overlap based 
on the conservative classification of symptoms. Alterna-
tively, the breadth of ME/CFS symptoms included in the 
ICC diagnostic criteria may inflate the findings. Reliance 
on qualitative symptom report comparisons only provide 
a preliminary guide to shared symptomatology. Whilst 
useful for theoretical purposes it is insufficient to draw 
confirmatory conclusions.
Implications
Mindful of these limitations, the proposal of a continuum 
of acute and chronic encephalopathy related to d-lac-
tate warrants further investigation. Within d-la, several 
authors have proposed that the level of acidosis and asso-
ciated encephalopathy may result in differing severity 
and either an acute or chronic presentation [27, 28, 32]. 
A subclinical elevation of d-lactate has been reported 
in SBS patients and diverse populations [94]. Higher 
d-lactate levels were recorded in 2.8% of randomly 
selected hospital patients [40]. Minimal details were pro-
vided about this sample other than noting that 40% of 
these patients did not have a history of gastrointestinal 
surgery [40]. Higher levels of d-lactate have also been 
recorded in response to trauma or infection [95]; and in 
patients with diabetes compared with healthy controls 
[96]. Thornalley et  al. [97] showed positive correlations 
between the level of d-lactate and duration of diabetes. 
They found that the duration of disease was positively 
associated with retinopathy, neuropathy and nephropa-
thy complications of diabetes. The relevance of d-lactate 
for diverse presentations is currently unknown.
Even within SBS populations, d-la has been under-rec-
ognised and frequently misdiagnosed [9]. Misdiagnosis 
is complicated by issues related to accurate and efficient 
measurement of d-lactate. A further diagnostic compli-
cation related to the clinical presentation of d-la is that 
the neurological manifestations can present without gas-
trointestinal complications or a change in gastrointestinal 
symptoms. Less than one-quarter of d-la episodes ana-
lysed in this review described a worsening of gastrointes-
tinal symptoms. Therefore, it is plausible that clinicians 
may focus on the neurological presentation and overlook 
the underlying gastrointestinal mechanism. The case 
report from Scully et  al. [70] highlighted this when the 
16-year old male patient was first treated by a psychiatrist 
with lithium carbonate for suspected bipolar disorder 
and tested for illicit drug use before being diagnosed with 
d-la. The patient presented with aggression, somnolence 
and weight loss without current gastrointestinal symp-
toms, although had an abdominal trauma one year prior 
that required short-bowel surgery [70]. The presence of 
neurological symptoms in the absence of current gastro-
intestinal symptoms may lead to frequent misdiagnoses. 
The proposed mechanisms of d-la (i.e., carbohydrate 
malabsorption and related bacterial overgrowth [32, 36]) 
may have relevance for patients presenting with neuro-
logical symptoms but without an observable change in 
gastrointestinal symptoms.
Carbohydrate malabsorption is not exclusive to SBS 
populations and can vary in severity. Altschule et al. [98] 
found that d-lactate was more slowly metabolised in 
patients with schizophrenia, manic-depression and psy-
chosis compared with healthy controls. Even earlier stud-
ies have shown increased lactate after fructose or glucose 
ingestion and disturbed lactate metabolism after exercise 
within these populations [98], suggesting difficulties with 
carbohydrate metabolism. Within ME/CFS, carbohydrate 
restriction (e.g., avoidance of sugars and grains) may be 
advantageous [99, 100]. Whilst there is minimal empiri-
cal support, clinical reports suggest that dietary trig-
gers can exacerbate symptoms and that some patients 
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benefit from dietary exclusions [99]. The response to 
treatment for small intestine bacterial overgrowth (SIBO) 
in ME/CFS patients [101], suggests that carbohydrate 
malabsorption may be relevant for a subgroup of this 
population. An analysis of mechanisms involved in d-
la is provided to help identify shared pathophysiology 
between d-la and ME/CFS.
Part B. Narrative review
Proposed mechanisms in d-lactic acidosis
Understanding d-la involves firstly establishing the rea-
son for increased d-lactate levels before examining pro-
posed neurological mechanisms. Figure  4 summarises 
the contextual factors, triggers and proposed mecha-
nisms leading to d-la. The presentation of d-la requires 
both an increase in d-lactate absorption that exceeds the 
metabolic and/or excretion capacity of the patient.
Bacterial dysbiosis
Bacterial dysbiosis (i.e., an imbalance in commensal 
bacteria [2]) has been suggested as the primary mecha-
nism influencing d-la presentation in SBS populations. 
The dysbiosis is distinguished by an increased colonisa-
tion of lactic acid-producing bacteria, particularly bac-
teria that produce d-lactate (e.g., Lactobacillus fermenti, 
L acidophilus, and Streptococcus; see review by Petersen 
[13]). An overgrowth of Lactobacilli has been identified 
in SBS patients with increased d-lactate levels [26, 28, 37, 
47, 64, 68, 72, 74, 75, 103]. This dysbiosis has been pro-
posed as a result of an impaired small intestine, either 
due to congenital causes, surgery for midgut volvulus, 
gangrene or inflammatory bowel disease [104]; func-
tional SBS and carbohydrate malabsorption [32, 36]; or 
colonic stagnation [62]. With reduced absorptive capac-
ity of the small intestine, malabsorbed carbohydrates are 
more likely to enter the colon and provide fuel for colonic 
bacteria leading to increased bacterial fermentation [54, 
81]. Increased bacterial fermentation can further reduce 
bowel motility [31], alter colonic pH and change the level 
of bacterial metabolites. This can include a reduction in 
volatile fatty acids [26] and increased d-lactate produc-
tion [shown in 26, 54, 64, 66, 75, 105].
Dietary, probiotic and antibiotic intake have preceded 
bacterial dysbiosis and d-la presentations. Some epi-
sodes of d-la have been triggered by increased sugars/
carbohydrate (e.g., [31, 42, 66]) or a change from paren-
teral to oral intake (e.g., [48, 70]). In patients with bac-
terial dysbiosis, diet and probiotic supplementation can 
increase bacterial fermentation and further alter bac-
terial composition. It appears that the type of diet or 
probiotics can influence d-lactate production in either 
a beneficial or detrimental manner. Whilst antibiotics 
are commonly used as a treatment for d-la, indiscrimi-
nate and inappropriate use of antibiotics has also been 
shown to precede and potentially trigger d-la [36]. The 
way antibiotics alter bacterial composition may lead to 
Fig. 4 Overview of mechanisms in d-lactic acidosis. Legend. Summary of contextual factors, triggers and proposed mechanisms leading to d-lactic 
acidosis (d-la). A presentation of d-la requires an increase in d-lactate absorption. The proposed mechanisms of increased d-lactate production can 
be through (1) bacterial dysbiosis and/or (2) endogenous production of d-lactate. Simultaneous to the increased absorption, patients who present 
with d-la also require (3) slowed metabolism of d-lactate. Hence, the d-lactate production exceeds the body’s metabolic and/or excretion capacity. 
Short bowel syndrome (SBS); d-2-hydroxy acid dehydrogenase (d-2-HDH); adenosine triphosphate (ATP); tricarboxylic acid (TCA)
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further dysbiosis and an increased d-lactate production 
in vulnerable patients.
Although bacterial dysbiosis is the primary mechanism 
used to explain the occurrence of d-la, enteric microbial 
composition was only measured prior to treatment for 
21 of the 59 episodes screened for the qualitative review 
(35.6%). More consistent measurement of the gut micro-
biome may add clarity to d-la etiology and individual 
treatment.
Slowed d‑lactate metabolism/excretion
Whilst it is beyond the scope of this review to explain lac-
tate metabolism (see [13, 106]) a brief overview of d-lac-
tate metabolism in relation to d-la is provided. Humans 
can effectively metabolise large amounts of d-lactate. 
Hove and Mortensen [15] confirmed that humans have 
the enzyme d-2-hydroxy acid dehydrogenase (d-2-HDH) 
to enable conversion of d-lactate to pyruvate. Certain 
conditions such as increased oxalate and low pH can 
inhibit the activity of d-2-HDH enzymes, as shown in 
animal tissue [107]. The kidney and liver have the high-
est concentrations of d-2-HDH. Therefore, kidney and 
liver impairments can reduce effective metabolism of 
d-lactate indicated by d-lactate accumulation in patients 
with renal dysfunction [40] and liver cirrhosis [108]. The 
presence of adequate d-2-HDH is required for d-lactate 
metabolism.
Colonic bacteria can be involved in both lactate pro-
duction and excretion during pyruvate metabolism. 
Human and some bacterial mitochondria have the 
enzyme dl-lactate racemase which enables conversion 
between d-and l-lactate [15]. For example, Lactobacillus 
species are common producers of lactate but the ratio of 
d- and l-lactate production and the direction of conver-
sion is dependent on the species (see [109]). Therefore, 
impaired colonic metabolism of d-lactate may also be a 
consequence of bacterial dysbiosis. Colonic flora that 
is predominated by lactate-producing bacteria and a 
reduced capacity to convert lactate to short chain fatty 
acids (SCFA) will result in less SCFA and reduced metab-
olism of d-lactate [13].
Impaired metabolism of consequential d-lactate accu-
mulation is required for the presentation of d-la [25]. 
It may be beneficial to categorise patients into lactate 
accumulators vs non-lactate accumulators. When exam-
ining bacterial composition in a sample of SBS patients, 
Mayeur et  al. [110] showed that some patients prefer-
entially accumulated d-lactate compared with l-lac-
tate, suggesting the influence of bacterial composition 
on d-lactate profiles. The d-lactate accumulators were 
more likely to experience encephalopathy symptoms. 
Therefore, multiple factors including increasing bacterial 
d-lactate production, other endogenous production of 
d-lactate, nutritional status and altered d-lactate metab-
olism will effect d-lactate accumulation and the clinical 
presentation of an episode of d-la.
Proposed neurological mechanisms in d-lactic acidosis
Metabolic acidosis and increased d-lactate levels are 
synonymous with the presentation of d-la. However, 
neither condition can predict the development of neuro-
logical symptoms. Acidosis can occur without associated 
neurological symptoms and in reverse, encephalopathy 
can be present without the accompanying acidosis [13]. 
Similarly, whilst increased d-lactate levels are required in 
d-la, the presence of high d-lactate is not the sole cause 
or determinant of neurological symptoms. Some stud-
ies have shown a temporal association between d-lactate 
level and symptom onset [30] as well as severity [103]. 
However, this has not always been replicated (e.g., [48]). 
Other factors must also be required because higher 
d-lactate levels have been shown in patients with SBS 
and other gastrointestinal disorders but without concur-
rent encephalopathy [111]. These inconsistencies suggest 
that there are several possible direct and indirect mecha-
nisms responsible for the neurological manifestations in 
d-la (see Fig. 5).
Possible pathways of gut–brain interaction
Three pathways have been proposed to explain how excess 
d-lactate production in the colon can impact neurologi-
cal symptoms [112]. Firstly, a colonic environment with 
lowered pH and high lactate levels can increase intesti-
nal permeability (i.e., aberrations in the mucosal lining 
of the gastrointestinal tract [113, 114]) and result in sys-
temic inflammation. For example, in ruminants, prelimi-
nary findings showed that lactic acidosis (lowered pH and 
increased faecal lactate) was significantly associated with 
increased tumor necrosis factor-alpha (TNF-α [115]). 
Translocation of luminal content, including endotoxins, to 
bodily fluid or tissue may result in an increased immune 
response and associated neurological sequelae [116].
A second pathway of gut–brain interaction is through 
neural mechanisms. The bidirectional communication 
between the enteric nervous system (ENS) and central 
nervous system (CNS) via the vagus nerve can regulate 
or dysregulate neurotransmitter production [117]. Bac-
terial dysbiosis can have both direct and indirect effects 
on neurotransmitter production and associated neuro-
logical symptoms (see [2]). Dahlquist et  al. [30] suggest 
that the effect of d-lactate on neurotransmitter produc-
tion is one possible explanation for the temporal associa-
tion between neurological symptoms and d-lactate levels 
observed during some d-la episodes. Alternatively, d-lac-
tate may act by reducing neuronal energy metabolism as 
explored below.
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Thirdly, excess d-lactate can act centrally in the colon 
and be absorbed and transported from the gut to the 
brain through the circulation. Hanstock et al. [112] pro-
vided support for this being a primary mode of action 
finding significant associations between plasma and 
colon/caecum d-lactate levels in rats. d-Lactate can cross 
the blood–brain barrier with evidence of d-lactate in 
both circulating plasma and cerebrospinal fluid in human 
case reports of d-la [48, 70]. Whilst murine models show 
reduced uptake of d-lactate compared with l-lactate 
within the brain [112], slowed metabolism due to low 
d-2-HDH in the brain may explain the subsequent neu-
rological symptoms [31]. An increased d-lactate level 
within the brain may exert direct and indirect effects on 
the CNS.
Proposed central nervous system mechanisms
Direct effect of d‑lactate As a substrate on its own, the 
direct neurotoxic effect of d-lactate is questionable and 
unlikely. Intravenous infusion of d-lactate in healthy 
males did not result in evidence of neurological symptoms 
[118]. However, at substantially higher levels, as shown 
in propylene glycol intoxication [43], or in combination 
with nutritional deficiencies [30], direct neurotoxic effect 
may be possible. d-Lactate may act as a “false neurotrans-
mitter” [30, p. 145]. Similar fluctuations in biochemistry 
concurrent with non-specific EEG abnormalities during 
an adult episode of d-la may support this proposal [74]. 
However, this remains propositional without further evi-
dence of the precise mechanisms involved.
The neuroprotective properties of d-lactate have also 
been described raising doubt about the neurotoxicity 
of d-lactate alone. Castillo et  al. [119] showed that both 
l- and d-lactate can exert neuroprotective properties in 
a male mouse model of cerebral ischemia (stroke). Unex-
pectedly, they found that d-lactate showed near equiva-
lent neuroprotective properties (i.e., reduced cell death, 
less damage observed on behavioural measures) to that 
shown with l-lactate. Unlike earlier findings, their results 
indicated that d-lactate can be metabolised by the rodent 
brain. This raises the possibility that d-lactate may also 
be able to be metabolised within human cerebral tissue. 
Notably this evidence is from a stroke animal model and 
requires investigation before generalising to d-la. It further 
highlights that d-lactate alone may not be neurotoxic but 
can play deleterious roles in certain environments when 
combined with other necessary conditions (e.g., nutri-
tional deficiencies, excess glutamate, or mitochondrial tox-
icity) to produce the encephalopathy observed in d-la.
It has also been proposed that d-lactate can inhibit 
l-lactate transportation [120]. Considering that l-lactate 
can have an inhibitory effect on the adrenal cortex [46], 
it could be surmised that excess d-lactate may reduce 
available l-lactate and consequentially increase adreno-
cortico activity. Further investigation of this mechanism 
is warranted. Growing evidence provides support for the 
role of d-lactate in energy metabolism.
Indirect effects of  d‑lactate and  implications for  energy 
metabolism Previous research has proposed that d-lac-
Excess absorption of D-
lactate
PROPOSED CNS MECHANISMS CLINICAL PRESENTATION
NEUROLOGICAL 
SYMPTOMS
Impaired lactate 
metabolism / excretion
D-LACTIC ACIDOSIS
1. Systemic inflammation from 
intestinal permeability
2. Direct effect on ENS through 
vagus nerve
3. Central absorption from the gut 
through the circulation to the brain
PATHWAYS OF GUT-BRAIN INTERACTION
Supporting Evidence Opposing Evidence
Direct effect of D-lactate
! Ability to cross blood-brain barrier [48, 70]
! Low D-2-HDH in the brain [31]
! Neurotoxic effects on CNS
! D-lactate as a false neurotransmitter [30]
! Impact on adreno-cortico activities [46]
! D-lactate can be metabolised
efficiently [118]
! Neuroprotective properties of D-
lactate [119]
Indirect effect of D-lactate and implications for energy metabolism
! Intraneural acidosis low pH can interfere with L-lactate 
metabolism [81]
! D-lactate as a metabolic substrate
! Inhibits transport of L-lactate, prevents L-lactate being 
used for neuronal energy [120]
! Interferes with pyruvate metabolism and consequential 
ATP (energy) and neurotransmitter production [22, 81]
! Impairs astrocyte metabolism [126]
! Increased lactate associated with decreased SCFA [13]
! Acidosis in isolation does not 
directly cause neurological 
symptoms [see 121]
Other (not D-lactate)
! Other metabolites
! Currently unidentified organic acids, and/ or unknown 
bacterial metabolites may cause simultaneous 
neurotoxic effects or impairment in energy metabolism 
similar to those proposed for D-lactate [128]
! Nutritional deficiencies
! Direct impact of thiamine, essential fatty acid, and or 
malabsorption on neurological symptoms [20, 41]
Fig. 5 Proposed mechanisms of gut–brain interaction leading to neurological symptoms observed in d-lactic acidosis. Supporting and opposing 
evidence for proposed central nervous system (CNS) mechanisms are categorised according to direct effects of d-lactate, indirect effects of d-lactate 
and other possible mechanisms unrelated to d-lactate. Abbreviations: enteric nervous system (ENS); d-2-hydroxy acid dehydrogenase (d-2-HDH); 
adenosine triphosphate (ATP); short chain fatty acids (SCFA)
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tate levels can reduce the pH balance within the brain and 
impede neurological processes [81]. Low pH can interfere 
with l-lactate metabolism [42]. However, in animal mod-
els it appears that the intraneural acidosis itself is not the 
primary mechanism at play (see [121]). Similarly in clini-
cal d-la cases, in isolation the acidosis does not directly 
cause neurological symptoms [32]. Reduced d-lactate is 
more closely related to clinical improvement than neu-
tralizing pH [39]. Bongaerts et al. [122] also showed that 
there was not a direct correlation between d-la and acido-
sis. Rather than intraneural acidosis, the competing role 
of l- and d-lactate for cerebral metabolism is a preferred 
explanation [121].
Pairing lactate and glutamate in the first in vivo stud-
ies in male rats demonstrated the neuroprotective prop-
erties of l-lactate and neurotoxic properties of d-lactate 
[120]. The mechanism appears to be related to d-lactate’s 
influence on energy metabolism. When d-lactate was 
combined with glutamate, larger cortical lesions were 
produced [120]. This result suggests that d-lactate inhib-
its transport of l-lactate and prevents l-lactate being 
used for neuronal energy. Ros et  al. [120] findings indi-
cate the compounding neurotoxic effects of d-lactate 
when combined with excess glutamate. In a comparable 
murine study, Cassady et al. [121] showed that compared 
to d-lactate, l-lactate is the preferred substrate for cer-
ebral energy. d-Lactate increased the excretion of amino 
acids and therefore was unable to act as an efficient meta-
bolic substrate [121]. Variable levels of glutamate and 
other amino acids may explain why some people experi-
ence neurological symptoms and others do not.
Overlap between symptoms of pyruvate metabolism 
disorders and d-la presentation suggest that d-lactate 
can interfere with pyruvate metabolism and consequently 
reduce energy (adenosine triphosphate: ATP) and neu-
rotransmitter production [81, 123]. Lower levels of a 
primary enzyme required for pyruvate metabolism, pyru-
vate dehydrogenase, have been found in the healthy cer-
ebellum [124]. An increased d-lactate level that further 
impedes pyruvate metabolism may explain the predomi-
nance of motor/cerebellar symptoms observed in d-la 
[81]. Pyruvate metabolism abnormalities can interfere 
with optimal mitochondrial energy production [123]. 
This has potentially more revealing implications for 
organs that require greater energy, such as the brain and 
heart [123]. Ling et al. [123] found that d-lactate was an 
inadequate metabolic substrate and produced lower res-
piration in murine brain and heart mitochondria, how-
ever equivalent respiration rates were shown in liver 
tissue. d-Lactate was shown to inhibit l-lactate and pyru-
vate metabolism in brain and heart tissue.
The inhibition of l-lactate by d-lactate effects memory 
formation in day old chickens [125, 126]. The impaired 
metabolism may not only occur in neuronal cells as sug-
gested by Baker and Edwards [125]. Gibbs and Hertz 
[125] results revealed that the inhibitory action of d-lac-
tate occurs in astrocytes either through an extracellu-
lar effect or an intracellular effect impairing pyruvate 
metabolism in astrocytic mitochondria. Astrocytes play 
a primary role in maintaining homeostasis in the brain, 
including regulating glutamate use and removal, neu-
ronal energy, and neuronal pH [127]. Gibbs and Hertz’s 
[125] results demonstrated that the presence of d-lactate 
prior to a learning task prevented memory formation, but 
memory loss was delayed by 20 min when d-lactate was 
injected 10 min after the learning task. The authors sug-
gest that impaired memory formation in day-old chicks 
is comparable with the encephalopathy observed in d-la. 
Therefore, similar mechanisms may be responsible for 
neurological symptoms in the mammalian brain.
Other possible mechanisms, not d‑lactate Most research 
has focused on d-lactate’s role in precipitating the neu-
rological symptoms observed in d-la. However, other 
metabolites and nutritional deficiencies may play causa-
tive and/or contributory roles in the encephalopathy 
observed in this condition. The suggestion to investigate 
other causative factors has been supported by evidence of 
increased d-lactate levels in healthy populations [14, 118] 
and poor direct association between d-lactate level and 
clinical symptoms [13]. Colonic bacteria can produce sev-
eral other metabolites (including alcohol, organic acids, 
amines, mercaptans, and aldehydes) that may exert neu-
rotoxic or neuromodulating effects by influencing neuro-
transmitter production [128]. Indirectly, higher d-lactate 
produced by an increased abundance of lactic-acid pro-
ducing bacteria may reduce the presence of other bacteria 
that metabolise SCFAs. The reduced availability of SCFA 
can impact energy metabolism and neurotransmitter 
production [13]. Currently unidentified organic acids or 
unknown bacterial metabolites may cause simultaneous 
neurotoxic effects or impairment in energy metabolism 
similar to those proposed for d-lactate [20].
As alluded to earlier, the nutritional deficiencies com-
monly present in SBS populations may exacerbate the 
clinical presentation [20]. Adequate nutrition is required 
for brain development with nutrient deficiency or insuf-
ficiency having both broad and specific effects on regions 
of the brain and neural functioning (see Georgieff [129]). 
Within d-la, nutritional deficiencies may directly impact 
neurological symptoms or the reduced availability of 
nutritional substrates may alter d-lactate metabolism, 
clearance or utilization within the brain. Hudson et  al. 
[40] presented a case report of a patient with d-la and 
thiamine deficiency where thiamine supplementation 
effectively resolved neurological symptoms. Interestingly 
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in Wernicke encephalopathy, another condition that 
presents with acute confusion, delirium and ataxia, thia-
mine deficiency is responsible for these neurocognitive 
symptoms that resolve once adequate thiamine levels are 
restored (see Latt and Dore [130]). Thiamine is required 
for effective pyruvate metabolism in the brain, particu-
larly within the cerebellum, hence thiamine deficiency 
may contribute to the encephalopathy seen in some 
patients with d-la.
Summary
There is more support for the indirect effect of d-lactate 
interfering with energy metabolism in the CNS com-
pared with the direct neurotoxic effects of d-lactate. 
Multiple mechanisms may be at play. Evidence of the 
inhibitory action of d-lactate on utilisation of l-lactate in 
neural cells and astroglia appears a particularly pertinent 
mechanism that may explain the neurological symptoms 
observed in d-la. The relevance of other bacterial metab-
olites remains in question. The vulnerability of certain 
individuals related to predisposing genetic, microbial fac-
tors or nutritional status that influence d-lactate produc-
tion and/or adequate excretion/metabolism is likely to 
contribute to the presentation of d-la.
What is the relevance for ME/CFS?
Whilst d-lactate levels have not been specifically meas-
ured in ME/CFS patients, elevated lactate levels within 
ventricular cerebrospinal fluid have been observed. 
Significantly higher levels of ventricular lactate were 
recorded in the ME/CFS patient group compared to both 
generalized anxiety disorder (GAD) and control groups. 
From this small sample of 16 CFS patients, 10 patients 
had high ventricular lactate levels, indicated by lactate 
levels above 2 standard deviations above control mean 
whereas the remaining 6 participants had equivalent lac-
tate levels to both the GAD and healthy control groups. 
This distinction between clinical and control groups gives 
promise for ventricular lactate being a potential bio-
marker useful for establishing ME/CFS subgroups. Inter-
estingly lactate level was not associated with any other 
demographic or clinical variables, including severity of 
illness. Notably, clinical measures of anxiety, depression, 
fatigue, sleep quality and fibromyalgia were used as out-
come variables but cognitive symptoms were not meas-
ured. More detailed analysis of associations between 
objective neurocognitive symptoms and ventricular lac-
tate level would be valuable. The authors explained the 
potential mechanisms related to mitochondrial dysfunc-
tion and/or oxidative stress that precede reduced cerebral 
blood flow which in turn upregulates anaerobic glycolysis 
and consequential lactate accumulation [131]. Mitochon-
drial dysfunction or increased oxidative stress may have 
bacterial and/or viral origins, or be related to underlying 
gastrointestinal abnormalities.
Gastrointestinal abnormalities
Examination of gastrointestinal abnormalities in ME/CFS 
indicate some similarities between d-la mechanisms and 
ME/CFS pathophysiology. Gastrointestinal dysfunction 
is included as one of the multiple symptoms in ME/CFS. 
Although not required for a diagnosis, gastrointestinal 
abnormalities and comorbid irritable bowel syndrome are 
frequently reported by patients with ME/CFS [132]. ME/
CFS patients more frequently experience gastrointestinal 
symptoms and use corresponding treatments (i.e., ant-
acids, H2 blockers, proton pump inhibitors) compared 
with healthy controls [133]. Estimates based on a clinical 
patient group of 1400 patients show recurring gastroin-
testinal symptoms are experienced by between 80 and 
90% of patients [134]. In a sample of 165 CFS patients, 
Chia and Chia [134] identified evidence of chronic 
inflammation and enterovirus of the stomach in 95 and 
82% of patient biopsies respectively. As the authors sug-
gest, the presence of viral markers in the stomach years 
after initial infection suggest that chronic viral infections 
of the stomach may contribute to continued pathophysi-
ology. Viral infections have been proposed to precipitate 
and perpetuate the bacterial dysbiosis observed in ME/
CFS (see review by Navaneetharaja et al. [135]).
Bacterial dysbiosis, antibiotic and probiotic treatment
Evidence of gut dysbiosis has been observed through 
measurement of fecal microbial composition in ME/CFS 
populations. Differences between microbial composi-
tion of healthy compared with ME/CFS populations have 
been reported using both culture-based [136, 137] and 
genetic sequencing methods [3, 138]. Treatment using 
antibiotic [139], probiotic [140–142] or bacteriother-
apy [143] have also been used to help modulate the gut 
microbiota in ME/CFS with somewhat unpredictable and 
varied success.
Using culture-based methods, we have previously 
observed a predominance of d-lactate producing bac-
teria (Enterococcus and Streptococcus species) in ME/
CFS patients [4]. These bacteria produce high levels of 
lactate in  vitro, compared with fecal isolates [4] which 
would support the maintenance of a more acidic colonic 
environment as one of the mechanisms in d-la that was 
previously described. This inference about the acidity of 
the colon in ME/CFS patients has been deduced from 
in vitro methods only, as we are not aware of any research 
that has measured colonic pH in this population. Within 
our prior clinical investigations, responders to a short-
term antibiotic treatment for Streptococcus overgrowth 
was associated with increased vigor on self-reports and 
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selected improvement on objective sleep markers [139]. 
Extending from these preliminary findings, we are cur-
rently examining interactions between microbiota, 
broader neuropsychological symptoms and d-lactate lev-
els in a clinical pilot evaluating treatment aimed at reduc-
ing an overgrowth of Streptococcus in a subgroup of ME/
CFS patients. Our group have also compared culture-
based fecal assessment and symptom expression within 
a larger sample (N =  274) of ME/CFS patients [5]. This 
observational study showed partial support for d-lactate 
theory in ME/CFS whilst raising questions about sex dif-
ferences. Significant positive associations between some 
lactate producing bacteria (Lactobacillus and Strep‑
tococcus genera) and ME/CFS symptoms were shown 
for males but not females [5, 144]. Notably, the relative 
abundance of genera measured was consistent across the 
sexes raising questions about the functional differences of 
microbiota or a differing response to d-lactate for males 
compared to females. The heterogeneity of presentation 
and differing response to treatments could have varied 
explanations. Through the d-lactate lens, a preferential 
uptake of d-lactate (i.e., d-lactate accumulation as pro-
posed by Mayeur et al. [110]) may contribute to variable 
symptoms and/or treatment response.
Using sequencing methods, Frémont et  al. [3] exam-
ined ME/CFS patients and healthy controls from Norway 
and Belgium. Comparison between patient and control 
groups revealed no significant difference in bacterial 
diversity across the groups but differences in composi-
tion were observed. When comparing Norwegian patient 
and control samples there was a significant difference in 
bacterial composition, with ME/CFS patients showing 
a lower proportion of genus within the Firmicutes phy-
lum. Interestingly, microbial differences between cultur-
ally diverse control samples (i.e., Norwegian compared 
with Belgian; [3] highlight the importance of considering 
inter-individual characteristics that may contribute to 
microbial variation.
Unlike Frémont et  al. [3] findings of similar bacte-
rial diversity, Giloteaux et al. [138] reported evidence of 
decreased diversity of microbial composition and insta-
bility in the microbial community in ME/CFS patients 
compared with controls. Significant differences were not 
shown when comparing the composition of ME/CFS and 
control samples at the phylum or genus level. However, 
at the operational taxonomic unit (OTU) level, propor-
tions significantly differed for 40 OTU’s. For example, the 
proportion of Faecalibacterium and Bifidobacterium was 
significantly lower in ME/CFS patients compared with 
controls. The few studies that have examined fecal micro-
bial composition in ME/CFS have shown some incon-
sistent results making current interpretation incomplete 
suggesting that evaluation of subgroups, species-level 
comparison and measurement of metabolites is required. 
Replication using a combination of culturing and genetic 
sequencing methods with larger samples and varied 
demographics will help ascertain the relevance of d-lac-
tate neurotoxicity in ME/CFS.
Bifidobacterium are high lactate-producing bacteria. 
Whilst the ratio of D/L lactate vary between species, a 
lower proportion of Bifidobacterium species raises some 
doubt about the relevance of d-lactate theory for ME/
CFS. Selected Bifidobacterium (Bifidobacterium ado‑
lescentis, Bifidobacterium breve) and Lactobacillus (L. 
plantarum, L. salivarius, L. casei subspecies rhamnosus, 
L. delbrueckii subsp. Lactis, L. acidophilus, L. fermentum, 
L. buchneri) species have been identified as predominant 
in patients with d-la [26, 28, 29, 37, 47, 54, 64, 68, 74, 75, 
145]. Similarity between species identified as overgrown 
in d-la patients and those used in probiotic studies could 
also generate skepticism about the relevance of d-lactate 
theory for ME/CFS. Both a small open-label [140] and 
two randomized, double-blind placebo-controlled studies 
[141, 142] examining the efficacy of probiotic supplemen-
tation in ME/CFS have indicated modest improvements 
for selected symptoms.
ME/CFS patients supplemented with a lactic-acid 
producing bacterial strain probiotic showed clinical 
improvement in self-reported neurological symptoms 
but no significant changes in fatigue or activity levels 
[140]. Rao et al.’s (2009) small double-blind RCT used an 
eight-week probiotic supplementation of Lactobacillus 
casei to examine changes in emotional symptoms. ME/
CFS patients in the treatment group reported a signifi-
cant reduction in anxiety symptoms compared with con-
trols. No change was recorded for subjective reports of 
depression. More recently, treatment using Bifidobacte‑
rium infantis 35,624 resulted in reduced inflammation in 
ME/CFS patients, however neurological symptoms were 
not measured [142]. Preliminary results indicate the need 
for further investigation of the efficacy of probiotic treat-
ment in ME/CFS. Of relevance to the current hypothesis 
in question, the d-lactate potential of selected strains 
used in the aforementioned studies is unknown. There-
fore, results from these treatment studies suggest support 
for gut–brain interaction in ME/CFS but fail to provide 
additional information about the relevance of d-lactate 
for this population.
Bacterial overgrowth in the small intestine may also 
have implications for d-lactate production. Logan et  al. 
[146] hypothesized that SIBO is involved in ME/CFS and 
related to the immune alterations observed in this con-
dition. SIBO can be a cause of functional short bowel 
and result in carbohydrate malabsorption. Patients with 
comorbid SIBO and CFS have shown clinical improve-
ment (on subjective reports of depression, memory/
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concentration and pain) following antibiotic treatment 
[101]. d-Lactate levels were not measured in this study 
but dependent on the type of bacterial overgrowth, 
excess production of bacterial metabolites (including but 
not limited to d-lactate) may act centrally, through ENS 
activation or systemically due to intestinal permeability.
Implications for gut–brain interaction
Systemic inflammation as a consequence of gut mucosal 
damage and intestinal permeability as the first proposed 
pathway of gut–brain interaction in d-la has also been 
suggested as a pathophysiological mechanism in ME/
CFS [116]. Initial support for this hypothesis in ME/CFS 
is reflected by findings of an increased immune response 
to lipopolysaccharide (LPS) (as measured by serum IgA 
and IgM to selected bacteria [116] and clinical improve-
ment after treatment to restore intestinal permeability 
[113]. Measurement of plasma levels of LPS have been 
used as an indicator of microbial translocation as they are 
produced in response to Gram-negative bacteria [138]. 
Chronic LPS stimulation can be measured by plasma 
sCD14 and plasma LPS-binding protein (LBP) levels 
[138]. Recently, additional evidence of intestinal perme-
ability in ME/CFS patients has been shown through sig-
nificantly higher proportions of plasma LPS, LBP and 
sCD14 compared with controls [138]. These results sup-
port the hypothesis of an inflammatory and/or immune 
response to microbial translocation that occurs when 
there is chronic gut mucosal damage and intestinal per-
meability in ME/CFS patients.
Nutritional deficiencies in ME/CFS
Nutritional status can be impaired for individuals with 
chronic health conditions and comorbid gastrointesti-
nal abnormalities. Nutritional deficiencies require care-
ful monitoring and treatment for ME/CFS patients [1]. 
Coenzyme Q10 (CoQ10) was shown to be significantly 
lower in the plasma of ME/CFS patients compared with 
healthy controls [147]. Treatment that includes nutri-
tional supplementation is frequently employed with 
CoQ10, magnesium, l-carnitine and S-adenosylmethio-
nine indicated as potentially beneficial for this population 
[148, 149]. Improvements in cognitive symptoms (men-
tal fatigue, attention, concentration) have been described 
after supplementation with acetyl-L-carnitine and prop-
ionyl-L-carnitine for patients with ME/CFS [150]. Cola-
bamin (B12) injections are proposed to exert effects by 
reducing oxidative stress [151] but the implications of 
B12 deficiency may also be relevant when considering the 
role of B12 in the TCA cycle and lactate metabolism (see 
[152]). Considering the impact of nutritional deficiencies 
in d-la, this may interact with the symptom presentation 
in ME/CFS and the potential for excess d-lactate accu-
mulation or issues with metabolism. Nutritional deficien-
cies in ME/CFS may have varied origins, including but 
not limited to, genetic vulnerabilities, stress, infection, 
inadequate dietary sources and/or impaired metabolism 
that are factors involved in the etiology of ME/CFS [153]. 
Dietary modifications appear helpful for some ME/CFS 
patients (self-report in [154]) and in clinical case reports 
[148]. Similarly, dietary treatments and reduced carbo-
hydrate intake were common recommendations for d-la 
patients (see Additional file 1: Table S1). It would be use-
ful to understand the role of diet as a potential moderat-
ing factor (precedent, perpetuating or consequential) in 
bacterial dysbiosis and d-lactate production in ME/CFS 
patients and whether this varies for moderately impaired 
compared to severely impaired (i.e., bedbound) patients.
Conclusions
d-la is an acute condition that provides a clear example 
of the microbe–gut–brain interaction with encepha-
lopathy similar to ME/CFS. Growing evidence supports 
the proposal of the microbiota–gut–brain interaction in 
ME/CFS. Specific mechanisms are yet to be confirmed. 
Our qualitative review of d-la case studies shows consid-
erable overlap between d-la and ME/CFS neurological 
symptoms. Subclinical levels of d-lactate may be related 
to fluctuating neurological symptoms in ME/CFS. Our 
review of the d-la literature has led us to propose the 
hypothesis that d-la and ME/CFS may lie on a contin-
uum, with notable distinctions related to differences in 
acute versus chronic presentations (see Fig. 3). Increased 
prevalence of d-lactate producing bacteria in an ME/
CFS sample compared with controls [4] provides the only 
clear evidence supporting d-lactate theory in ME/CFS. 
Gut dysbiosis in fecal microbiota, SIBO, and preliminary 
responses to antibiotics warrant measurement of d-lac-
tate levels in this clinical population.
We acknowledge the complexity and heterogene-
ity of ME/CFS. Explanation of other pathophysiological 
mechanisms in ME/CFS (including but not limited to 
neuro-immune, oxidative stress and inflammatory path-
ways, [116, 147, 153, 155, 156] was beyond the scope of 
the current review. We stress that d-lactate theory may 
be relevant for a select subgroup and if not causative, may 
be a factor that perpetuates or exacerbates neurological 
symptoms. To date, there is no research that has meas-
ured d-lactate levels in ME/CFS. Improved efficiency and 
availability of d-lactate measurement in urine and blood 
samples is needed. Measurement of d-lactate will clarify 
its role of d-lactate in this population and may generate 
an avenue for alternative treatments. Subclinical levels of 
d-lactate in diverse populations suggest that this may be 
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extended to other conditions. The proposed continuum 
is relevant for general physicians, gastroenterologists, 
psychiatrists and psychologists alike. Awareness of gas-
trointestinal origins for neurological presentations may 
hasten diagnostic accuracy, prevent misdiagnosis and 
improve treatment outcomes.
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